ADMA Biologics (ADMA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Company overview and product differentiation

• Vertically integrated U.S.-based manufacturer of specialty intravenous immunoglobulin products with three FDA-approved offerings: ASCENIV, BIVIGAM, and Nabi-HB.

• Holds patents on plasma donor identification, immunoglobulin composition, and unique immunization schedules, enabling differentiated products.

• All operations, including plasma collection, manufacturing, and testing, are U.S.-based, with 10 internal plasma centers and new decade-long third-party supply contracts.

Supply chain, manufacturing, and capacity

• Manufacturing facility has 600,000-liter annual capacity, producing over 2 million grams of immunoglobulin annually.

• Manufacturing cycle time is 7–12 months, providing strong forward visibility for commercial planning.

• New supply contracts expand plasma sourcing from 50–70 to over 250 U.S. centers, expected to be fully onboarded by mid-2025.

• No plans to expand beyond 10 internal centers; focus is on leveraging third-party contracts for growth.

Market landscape and growth drivers

• U.S. immunoglobulin market was $12B in 2023, expected to exceed $20B by 2030, with high per-capita usage and pricing.

• Company holds 2% unit share and 3.5–4% revenue share, benefiting from higher-margin products.

• All industry producers sell everything they make due to supply-demand imbalance, driven by aging population and better diagnostics.